Published in Drug Law Weekly, February 8th, 2005
This is an increase of 17%, or $3 million, from third-quarter 2004 Cubicin revenue. Full 2004 year-end net revenues were $58.6 million (unaudited) which is in the high end of the company's 2004 earnings revenue guidance of $55-60 million.
Michael W. Bonney, president and CEO, stated, "With just over a full year of sales now completed, we take great pride in the confirmation that the launch of Cubicin is in fact the most successful IV [intravenous]...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.